2024 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Policy & Regulation
Amid the evolving regulatory landscape, small molecule innovation is impacted by the Inflation Reduction Act (IRA), China is hit with compliance crackdowns and India’s reign on e-pharmacies is questioned.
Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression
R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.
Storm Coming? Commercial Compliance Crackdown Shocks China Pharma Industry
In a new wave of crackdowns on compliance in the pharma sector in China, 10 medical meetings have been cancelled in short order, while sector-wide stock prices have plunged and 100 hospital officials placed under investigation, shocking the industry.
Heat On E-Pharmacies In India -The Shape Of Things To Come
India is expected to rein in the ‘unfettered’ run of e-pharmacies, a segment where top Indian conglomerates and Amazon have made strides, with pharma intertwined having tapped into these platforms. Scrip speaks to experts on areas of concern including prescription ‘workarounds’, supply chain transparency and data privacy where more oversight is called for amid the evolving regulatory landscape.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.